

**Strong gene dose dependent protective effect of Mediterranean type  
glucose-6-phosphate dehydrogenase deficiency against *Plasmodium vivax* malaria**

Running title: **G6PD deficiency and vivax malaria**

Ghulam R. Awab<sup>1,2</sup>,

Fahima Aaram<sup>3</sup>,

Natsuda Jamornthanyawat<sup>4</sup>,

Kanokon Suwannasin<sup>4</sup>,

Watcharee Pagornrat<sup>4</sup>

James A Watson<sup>1,5</sup>,

Charles J Woodrow<sup>1,5</sup>,

Arjen Dondorp<sup>1,5</sup>,

Nicholas PJ Day<sup>1,5</sup>,

Mallika Imwong<sup>4</sup>,

Nicholas J. White<sup>1,5</sup>

1. Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
2. Nangarhar Medical Faculty, Jalalabad, Afghanistan
3. Kabul Medical University, Kabul, Afghanistan
4. Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
5. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK

## Background

X-linked glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common human enzymopathy. The severe Mediterranean variant (G6PDd Med) is common across Europe and Asia. Epidemiological studies investigating the potential protective effect of G6PD deficiency against malaria have yielded conflicting results.

## Methods

G6PDd Med genotyping was performed in Pashtun patients in Afghanistan with acute *Plasmodium vivax* malaria and Pashtun subjects attending the same study centres with unrelated conditions or for routine vaccinations. A Bayesian statistical model assuming Hardy-Weinberg equilibrium was used to estimate the potential protective effects of G6PDd Med on vivax malaria, and was fitted to all available data from this and previous studies.

## Findings

In patients with vivax malaria 1.6% (5 of 308) of males were G6PD Med hemizygotes compared with 8.2% (28 of 342) of controls (risk ratio; 95% confidence interval: 0.198 [0.078 to 0.507]), and 6.8% (31 of 458) of female patients were heterozygotes compared with 11.2% (40 of 358) of controls (RR 0.606 [0.387 to 0.948]). From all available data, the estimated allele frequency of G6PDd Med in the Pashtun is 8.8% (95% credible interval, 7.5-10.2). In hemizygous males and homozygous females, G6PDd Med confers a strong protective effect against symptomatic *P. vivax* malaria reducing the incidence by 73% (95% C.I. 53-87). In heterozygous females the estimated protective effect was 56% (95% C.I. 40-69). The protective effect in heterozygous females is 0.78 (95% CI, 1.09-0.53) of that observed in hemizygous males and homozygous females.

## Interpretation

The G6PD Mediterranean genotype confers a very large and gene dose proportional protective effect against vivax malaria. The proportion of patients with vivax malaria at risk of haemolysis following 8-aminoquinoline radical cure is substantially overestimated by epidemiological studies in healthy subjects.

**Keywords:** glucose-6-phosphate dehydrogenase deficiency, G6PD, *Plasmodium vivax*, malaria, primaquine, enzymopathy.

The authors have no conflicts of interest

**Financial support:** Wellcome Trust: Major Overseas Programme-Thailand Unit Core Grant:

106698/B/14/Z

**Correspondence:** Professor NJ White, Mahidol-Oxford Tropical Medicine Research Unit (MORU),

Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Rd, Bangkok, 10400, Thailand.

[nickw@tropmedres.ac](mailto:nickw@tropmedres.ac)

## 1 **Introduction**

2 In red blood cells glucose-6-phosphate dehydrogenase (G6PD; EC 1.1.1.49) is the only source of  
3 reduced nicotinamide adenine dinucleotide phosphate (NADPH) [1,2]. G6PD deficiency reflects  
4 instability, not absence, of the enzyme which is essential for normal cellular function. Mammalian  
5 erythrocytes lack nuclei and the necessary protein synthetic pathway and so, unlike nucleated cells,  
6 they cannot replenish degraded G6PD. As a result, in G6PD deficiency, older red cells become  
7 increasingly deficient. NADPH is essential for maintenance of oxidant defences. Thus, as G6PD  
8 deficient red cells age they become increasingly susceptible to oxidant haemolysis. G6PD deficiency  
9 is the most common enzyme abnormality in humans. It is found across the malaria endemic world  
10 with mutant gene prevalences up to 35% (average 8-10%) [3]. There are over 180 different  
11 polymorphic variants, most of which result in enzyme deficiency, but the degree of deficiency (from  
12 accelerated enzyme degradation) and thus vulnerability to oxidant haemolysis varies substantially  
13 among the different genotypes. G6PD deficiency is X-linked so males are either normal or fully  
14 deficient. Women display these two phenotypes (normal or homozygous deficiency) as well as  
15 intermediate deficiency (heterozygotes). Such females are genetic mosaics as a result of early  
16 embryonic random X-chromosome inactivation (Lyonisation). Their blood contains a mixture of  
17 G6PD normal and G6PD deficient erythrocytes. Overall, at a population level, the proportion  
18 averages 50:50 of each cell type, but there is inter-individual variation so in some heterozygotes the  
19 large majority of erythrocytes are G6PD deficient. The high prevalences of G6PD deficiency in  
20 tropical areas, particularly in Africa, and in areas where malaria was once endemic, suggest that  
21 G6PD deficiency confers protection either against malaria or its adverse effects. But the mechanism  
22 of protection is unclear and this has been a subject of controversy and divergent opinion, with no  
23 clear conclusion. Claims have been made that there is no malaria protective effect provided by G6PD  
24 deficiency, or that protective effects are seen in female heterozygotes only, or in male hemizygotes  
25 only, or in both [4-11]. Most of the studies addressing this question have focussed on falciparum  
26 malaria in Africa where the majority of evidence supports a protective effect against severe malaria,

27 particularly in female heterozygotes [10,11]. Whether male hemizygotes and female homozygotes  
28 are protected is unclear with evidence both for and against. A recent meta-analysis of 28 studies  
29 concluded that there was no significant protection from uncomplicated falciparum malaria overall  
30 (OR: 0.77; 95% CI 0.59 to 1.02) [4].

31 In 2002 Richard Carter and Kamini Mendis suggested that the evolutionary force selecting G6PD  
32 deficiency could have been either *Plasmodium falciparum* or *Plasmodium vivax* [12]. Historically *P.*  
33 *vivax* had a wider geographic distribution, although it has now been eradicated from North America,  
34 Europe and Russia. Elsewhere in the Americas, the horn of Africa, Asia and Oceania *P. vivax* has  
35 become the predominant cause of malaria in recent years. In general the variants of G6PD deficiency  
36 that are prevalent in these areas where *P. vivax* infections occur, or once occurred, are more severe  
37 than the common (“A-”) variant prevalent in the sub-Saharan African populations (in whom *P. vivax*  
38 malaria is rare and *P. falciparum* comprises the large majority of malaria infections), and in peoples  
39 with their genetic origin there. The most severe of the commonly found G6PD variants is the  
40 “Mediterranean” variant (“G6PD Med”). This results from a single C-T transition at nucleotide  
41 position 563, causing a serine phenylalanine replacement at amino acid position 188. G6PD Med is  
42 the predominant genotype in the Pashtun who live in Afghanistan, Pakistan and India [13-15]. To  
43 characterise the possible protective effects of G6PDd Med against *P. vivax* malaria, we conducted a  
44 retrospective analysis of case-control data from clinical studies on vivax malaria, and epidemiological  
45 studies of G6PD deficiency that we have conducted in Afghanistan over the past ten years. These  
46 data were then combined in a meta-analysis using all previously published data on G6PD deficiency  
47 in people of Pashtun ethnicity living in malaria endemic areas.

48

## 49 **Methods**

### 50 **Study Area and Participants**

51 In Afghanistan, malaria is confined to the northern plains, the Jalalabad basin and river valleys which  
52 fringe the central mountains to the west and south (Figure 1). Malaria cases begin presenting in

53 May, peak in July and August, and then decline with few cases seen after November. These studies  
54 were conducted over 10 years between 2009 and 2019.

55 The initial epidemiological study to assess the prevalence and genotypes of G6PD deficiency in  
56 Afghanistan was undertaken in one urban centre in each of nine provinces: Jalalabad (Nangarhar  
57 province), Mehtherlam (Laghman), Asadabad (Kunar), Maimana (Faryab), Taloqan (Takhar),  
58 Imamsahib (Kunduz), Pulikhumri (Baghlan), Pulialam (Lowgar) and the capital, Kabul (Kabul province)  
59 [15]. Provinces were chosen on the basis of practical accessibility combined with having a high risk of  
60 vivax malaria (>1 case/1000 population/year), the exceptions being Kabul and Lowgar which have  
61 low malaria transmission. This analysis is restricted to the Pashtun ethnic group who live in the  
62 higher *P. vivax* transmission areas for two main reasons; the Pashtun comprise the majority of  
63 people in the Eastern provinces where malaria incidence is highest, and G6PD variants other than  
64 G6PD Med are rare in this ethnic group [13,14].

65 In the initial prevalence study in healthy subjects conducted in 2009 only males were studied [16]. A  
66 convenience approach to sampling was used for reasons related to security. EDTA blood was  
67 obtained from healthy male adults and children attending outpatient medical laboratories with non-  
68 febrile illnesses or neighbouring vaccine administration who did not have malaria. Samples were  
69 transferred to filter-paper blood spots and stored in plastic zip-lock bags with silica gel at room  
70 temperature before transport to Bangkok for genotyping [15]. In later prospective studies conducted  
71 in 2018 and 2019 subjects (both male and female) attending outpatients and those attending  
72 immunisation centres were sampled in the same way from the same sites in Nangarhar province as  
73 the clinical malaria studies (Figure 1).

#### 74 **Clinical Studies**

75 Patients with malaria presented to provincial malaria control centres adjacent to the Pakistan  
76 border. Jalalabad, the capital city of Nangarhar province, is a referral centre for the whole eastern  
77 region. Population movement takes place in both directions across this largely mountainous area

78 bordering Pakistan. The malaria treatment protocols have been reported previously [16]. Patients  
79 (aged >6 months) or older presenting with uncomplicated microscopy confirmed symptomatic vivax  
80 malaria were enrolled if they or their carer gave fully informed written informed consent. Inclusion  
81 criteria were mono-infection with *P. vivax*, axillary temperature  $\geq 37.5^{\circ}\text{C}$  or oral/rectal temperature  
82  $\geq 38^{\circ}\text{C}$ , or history of fever in preceding 24 hours, and able to swallow oral medication and comply  
83 with study requirements. Exclusion criteria were any clinical or laboratory feature of severe malaria,  
84 significant comorbidity, known hypersensitivity to any study drugs, mixed species *Plasmodium*  
85 infection and pregnancy or lactation. In the initial studies patients with haemoglobin concentrations  
86  $\leq 8\text{g/dl}$  were excluded but in the later observational studies anaemic patients were not excluded.

### 87 **Laboratory procedures**

88 Capillary blood was collected for haemoglobin measurement (HemoCue<sup>®</sup>), Giemsa-staining of thick  
89 and thin blood films for parasite speciation and counts and G6PD testing. Before 2018 G6PD deficiency  
90 screening used the G-6-PD OSMR 2000 (R&D Diagnostics) and NADPH fluorescent spot test kit (10  
91 minutes incubation). From 2018 the CareStart<sup>®</sup> rapid test was substituted. Dried blood spots were  
92 stored for later genotyping [14,16]. Genomic DNA was extracted using the QIAamp<sup>®</sup> DNA Mini Kit  
93 (QIAGEN, Germany). Eluted genomic DNA samples were frozen at  $-20^{\circ}\text{C}$  until PCR amplification. All  
94 samples were subjected to PCR-RFLP to assess the G6PD Mediterranean variant in exon 6, based on  
95 the protocol of Samilchuk et al [18] with modifications including use of  
96 primers [F14948](#) and [R15158](#) at 250 nM, a 2  $\mu\text{l}$  volume of each genomic DNA template, and a final  
97 reaction volume of 30  $\mu\text{l}$  containing 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 1 mM  $\text{MgCl}_2$ , 125  $\mu\text{M}$  4-  
98 deoxynucleotide triphosphate (dNTPs), and 0.05 units Platinum<sup>®</sup>Taq DNA polymerase (Invitrogen,  
99 Brazil). After pre-denaturation at  $95^{\circ}\text{C}$  for 5 min, 45 PCR cycles were performed involving  
100 denaturation at  $94^{\circ}\text{C}$  for 1 min, annealing at  $55^{\circ}\text{C}$  for 1 min and extension at  $72^{\circ}\text{C}$  for 1 min, with  
101 post-extension at  $72^{\circ}\text{C}$  for 7 min. 10  $\mu\text{l}$  of each PCR product was digested with 10 units of the  
102 restriction enzyme *MbolI* (New England Biolabs Inc.) at  $37^{\circ}\text{C}$  for 3 hours and visualized by 2%

103 agarose gel electrophoresis. A product pattern of 104+98+28 bp indicates the G6PD Med mutation,  
104 whereas 202+28 bp indicates wild-type. All PCR products of samples with mutant type and 10% of  
105 the wild type samples were purified subsequently and the DNA was sequenced (Macrogen, Korea).  
106 Gene sequences of the PCR amplification products of *g6pd* (accession number: NM\_001042351.2)  
107 were confirmed using the NCBI's Blastn and Blastx programmes. Gene polymorphisms were assessed  
108 by comparison with the reference sequences using BioEdit v7.2.5.

109 **Additional data included in the meta-analysis assessing the protective effect of G6PD deficiency**

110 A systematic literature review identified two other sources of relevant data in Pashtun subjects.  
111 Bouma et al [13] described a phenotyping survey in male Afghan and Pakistani Pashtun refugee  
112 schoolchildren (Safi and Mamund tribes, respectively). Leslie *et al* [14] described a *P. vivax* case-  
113 control study, with the majority of individuals from the Safi and Mamund tribes. This relied mainly  
114 on phenotyping (except for heterozygous females). In the meta-analysis the phenotyping of males  
115 was assumed to be 100% sensitive and specific for the G6PD Med genotype.



116

## 117 **Statistical analysis**

118 To estimate the degree of protection against vivax malaria and investigate a possible gene-dose  
119 effect, we analyzed all the available data under a Bayesian statistical model that estimates the  
120 relative risk reduction. We chose this model structure instead of a logistic regression with the allele  
121 as the predictive variable and the case-control status as the outcome (the usual model choice for  
122 genetic case-control studies) because we can assume that the protective effect in G6PD deficient  
123 hemizygous males and homozygous females is the same due to Lyonisation (from a red cell  
124 perspective, they are identical). Log-odds estimated from a logistic regression model are not  
125 collapsible, therefore this assumption cannot be input into a logistic regression model. Our  
126 formulation, in terms of relative reduction, allows for this assumption to be hard-wired into the  
127 model.

128 The model assumed that Hardy-Weinberg equilibrium held in the studied population(s). The  
129 unknown overall allele frequency of the Mediterranean variant of G6PD deficiency is denoted  $p$ . The  
130 total number of healthy males (controls) sampled is denoted  $N_{males}^{healthy}$ ; the total number of *P. vivax*  
131 infected males (cases) is denoted  $N_{males}^{vivax}$ ; within these groups, the number of hemizygote deficient  
132 males are denoted  $N_{males}^{healthy,HemiD}$  and  $N_{males}^{vivax,HemiD}$ , respectively. The same notation is used for the  
133 female subjects, except that the superscript *HetD* refers to heterozygous deficient, and *HomoD*  
134 refers to homozygous deficient.

135 The likelihood of the observed data for the non-malaria controls is given by:

$$N_{males}^{healthy,HemiD} \sim \text{Binomial}(N_{males}^{healthy}, p)$$

$$N_{females}^{healthy,HomoD} \sim \text{Binomial}(N_{females}^{healthy}, p^2)$$

$$N_{females}^{healthy,HetD} \sim \text{Binomial}(N_{females}^{healthy}, 2p[1 - p])$$

136 The likelihood of the observed data for the vivax malaria cases is given by:

$$N_{males}^{vivax,HemiD} \sim Binomial(N_{males}^{vivax}, \alpha p)$$

$$N_{females}^{vivax,HomoD} \sim Binomial(N_{females}^{vivax}, \alpha p^2)$$

$$N_{females}^{vivax,HetD} \sim Binomial(N_{females}^{vivax}, \beta 2p[1 - p])$$

137 The parameter  $\alpha$ , such that  $0 \leq \alpha \leq 1$ , denotes the vivax malaria protective effect of hemi- and  
138 homozygous deficiencies, which are assumed to be identical. A value of  $\alpha=1$  implies no protective  
139 effect, and  $\alpha=0$  implies a complete protective effect. Thus  $1-\alpha$  is the relative reduction in prevalence  
140 in hemi/homozygous G6PD deficient *P. vivax* malaria cases compared to the controls. The parameter  
141  $\beta$ , such that  $0 \leq \beta \leq 1$ , denotes the protective effect of heterozygous G6PD deficiency with the same  
142 interpretation.

143 Weakly informative Bayesian priors were subjectively chosen as follows:

144  $\alpha \sim \text{Uniform}[0,1]$

145  $\beta \sim \text{Uniform}[0,1]$

146  $p \sim \text{Beta}(2,18)$

147 This model allows for an additive effect (i.e. the protective effect in heterozygous females is less  
148 than in homo/hemi-zygotes), or an increased effect in heterozygotes (expected under a model of  
149 balancing selection driven by heterozygous advantage). The Bayesian model was written in *stan* and  
150 a reproducible implementation of the results in *rstan* is provided in the supplemental materials. Four  
151 independent chains were run for  $10^6$  iterations, with the first half discarded for burn-in and second  
152 half thinned every 200 iterations, to give a total of 10,000 samples for the posterior distribution.  
153 Effect estimates and uncertainty levels are reported as mean posterior estimates with 95% credible  
154 intervals (2.5% and 97.5% quantiles of the posterior distribution).

155

156 **Ethical approval**

157 The clinical studies were approved by the Institutional Review Board of the Afghan Public Health  
158 Institute, Ministry of Public Health, Afghanistan, the Ethics Committee of the Faculty of Tropical  
159 Medicine, Mahidol University, Thailand, and the Oxford Tropical Research Ethics Committee, Oxford  
160 University, UK. The clinical trial was registered with the clinical trials website  
161 <http://www.clinicaltrials.gov/ct> under the identifier NCT01178021.

162

163 **Results**

164 In total 766 Pashtun patients presenting with acute vivax malaria (308 males, 458 females) and 699  
165 Pashtun controls (342 males, 357 females) were studied; 236 healthy males came from the  
166 epidemiology study reported previously [16] and the remaining control subjects came from the same  
167 locations as the clinical malaria studies (Table 1; Figure 1). From these data the allele frequency of  
168 G6PD Med was estimated to be 7.8% (95% credible interval (C.I.), 6.3 to 9.5) under an assumption of  
169 Hardy-Weinberg equilibrium. The proportions of G6PD Med male hemizygotes and female  
170 heterozygotes were substantially lower in patients with acute vivax malaria than in people  
171 incidentally visiting clinics or vaccination centres who did not have malaria (Table 1). Only 1.6% (5  
172 out of 308) of males with vivax malaria were hemizygotes (risk ratio; 95% confidence interval: 0.12  
173 [0.08 to 0.51]) while in the females with vivax malaria 6.8% (31 of 458) (RR 0.61 [0.39 to 0.95]) and  
174 0.7% (3 of 458) were heterozygotes and homozygotes respectively. Under the Bayesian model,  
175 assuming Hardy-Weinberg equilibrium, these results suggest that G6PDd Med hemizygous males  
176 and homozygous females have 67% (95% C.I. 40-85) protection (i.e. relative reduction) against acute  
177 *P. vivax* malaria and G6PDd Med heterozygous females have 51% (95% C.I. 30-68) protection.

178 These results were then combined with data from the two previously reported studies on the  
179 prevalence of G6PD deficiency in the Pashtun ethnic group from Afghanistan. One was in healthy  
180 subjects only [13] and the other included both vivax malaria patients and healthy control subjects

181 [14]. (Table 1). The meta-analysis of all three studies gave a slightly higher G6PD Med allele  
182 frequency of 8.8% (95% C.I., 7.5-10.2). The overall protective effect in male hemizygotes and female  
183 homozygotes was estimated as 73% (95% C.I., 53-87) and in female heterozygotes was 56% (95%  
184 C.I., 40-69). The posterior distributions for these estimates from the meta-analysis are shown in  
185 Figure 2. The posterior probability that the protective effect observed in female heterozygotes was  
186 less than the protective effect observed in male hemizygotes and female homozygotes was 0.93,  
187 suggesting that the protective effect is proportional to the gene-dose.

188

## 189 Discussion

190 The Mediterranean type glucose-6-phosphate dehydrogenase deficiency (G6PDd Med) prevalent in  
191 the Pashtun provided a strong and gene-dose related protective effect against *Plasmodium vivax*  
192 malaria. This is a much greater protective effect than observed against *P. falciparum* malaria  
193 elsewhere [4, 10]. This much larger protective effect against vivax malaria observed in this large  
194 study is probably explained by two factors; the degree of enzyme deficiency with G6PD Med is  
195 substantially greater than in the common African A- variant, which has been the main genotype  
196 studied previously, and *P. vivax* is generally more sensitive to oxidant effects than *P. falciparum*.  
197 Compared with *P. falciparum*, asexual stages of *P. vivax* are also more sensitive to oxidant drugs (i.e.  
198 artemisinins and synthetic peroxides and 8-aminoquinolines) [19, 20]. *P. vivax* may therefore be  
199 more sensitive to the oxidant stresses associated with G6PD deficiency. This large study from  
200 Afghanistan confirms earlier findings from a case control study in Afghan Pashtun refugees, based  
201 mainly on phenotyping. This earlier study showed clear evidence of protection against vivax malaria  
202 in male hemizygotes, but the effect (adjusted odds ratio: 0.4, 95%CI 0.16 to 1.02) in the smaller  
203 subgroup of genotyped female heterozygotes was of borderline significance [13]. These earlier  
204 studies, and a smaller series from Iran with phenotyping [21], are consistent with the present series.  
205 Combined together they show clearly that G6PDd Med provides a substantial gene dose  
206 proportionate protection against vivax malaria. In a survey conducted in periurban Manaus, in the

207 Amazon region of Western Brazil, where *P. vivax* is now the predominant (90%) cause of malaria,  
208 there was also a very strong protective effect of G6PD Med against self-reported previous malaria  
209 (AOR: 0.010) [22]. In comparison the protective effect of G6PD A- in the same location was much  
210 weaker (AOR 0.119). This marked protective benefit is critically important for the assessment of  
211 population haemolytic risk associated with giving 8-aminoquinoline antimalarials for the radical cure  
212 for vivax malaria. The proportion of patients with vivax malaria at risk of serious haemolysis with  
213 G6PD Med is nearly four times lower than would be predicted from gene frequencies in the healthy  
214 population.

215 G6PD Med is among the most severe of the polymorphic genetic G6PD variants. It is found  
216 across the malaria endemic regions of the world, having evolved independently on several occasions  
217 [15, 23]. There is also evidence for protection against vivax malaria from the moderate severity  
218 G6PD Mahidol variant. A study from western Thailand found that *P. vivax* densities were lower in  
219 hemizygote males and also in heterozygote females presenting to clinics with vivax malaria, but  
220 there was no corresponding effect in falciparum malaria, and there was no apparent protective  
221 effect against malaria illness [24]. However, a study from Northern Myanmar showed G6PD Mahidol  
222 did protect against symptomatic vivax malaria, but with similar effects in male hemizygotes and  
223 female heterozygotes [25]. In a multi-site survey of G6PD deficiency in malaria patients in Cambodia,  
224 where G6PD Viangchan predominates (WHO class 2 but quantitatively similar to G6PD Mahidol),  
225 phenotypic severe deficiency (i.e. <10% of population normal) provided stronger protection against  
226 *P. vivax* than *P. falciparum* infections (OR: 0.45 95%CI 0.32 to 0.64) [26]. Conversely Dewasurendra  
227 *et al* in Sri Lanka reported evidence of hemizygote protection from malaria and lower parasite  
228 densities for *P. falciparum* but not *P. vivax* [27].

229 A recent meta-analysis of 28 studies [4] addressing the question of whether G6PD deficiency  
230 protects against malaria concluded that there was no significant protection from uncomplicated  
231 falciparum malaria overall (OR: 0.77: 95% CI 0.59 to 1.02), but that in subgroup analyses there was  
232 statistically significant evidence for protection in Africa (OR 0.59 95%CI 0.40 to 0.86) but not in Asia

233 (OR 1.24 95% CI 0.96 to 1.61). The degree of protection was similar in female heterozygotes (OR 0.7  
234 95%CI 0.57 to 0.87) and in male hemizygotes and female homozygotes (OR 0.7 95%CI 0.46 to 1.07)  
235 but did not reach statistical significance in the latter group. There was also evidence for publication  
236 bias towards significant findings in the uncomplicated malaria comparisons. The same meta-analysis  
237 also concluded that there was no statistically significant protective effect in severe malaria or in  
238 *Plasmodium vivax* malaria, although there were limited data to assess the protective effects in *P.*  
239 *vivax* infections.

240         The degree of protection conferred by G6PD Med against *P. vivax* illness estimated in this  
241 study is large; it is similar in magnitude to the well described protection conferred by Hb AS (sickle  
242 cell heterozygotes) against falciparum malaria [28]. It is possible that G6PD deficiency confers no  
243 significant protection against infection by *P. falciparum* but protects only against life threatening  
244 illness. This may reflect either inhibition of parasite multiplication or a different protective  
245 mechanism. One consistent clinical feature of G6PD deficiency is an increased risk of anaemia in  
246 acute infections as the deficient cells haemolyse [10,11]. As severe anaemia (Hb <5g/dL) is one of  
247 the criteria for defining severe malaria this results in a higher proportion of patients with G6PD  
248 deficiency presenting with severe malarial anaemia, and therefore being diagnosed as having severe  
249 malaria. This biases genetic association studies [29]. It has been suggested that G6PD deficiency may  
250 protect specifically against cerebral malaria, but a simpler explanation is that in the context of severe  
251 falciparum malaria, a rapid onset of moderate anaemia may protect against life threatening  
252 complications such as cerebral malaria [30,31].

253         There are several limitations to this study. It was not designed prospectively as a case  
254 control study. It combines results from a prospective epidemiology study conducted six years ago  
255 and prospective clinical trials and sampling of controls from the same centres from 2018. For  
256 security reasons careful matching of cases and controls (other than for location) was not possible.  
257 However, in the earlier study by Leslie et al [14], conducted in refugee camps in Pakistan, careful  
258 matching was done, particularly with reference to tribe (within the Pashtun group) and location, and

259 that study's findings are consistent with the present investigation. Nevertheless, it remains possible  
260 that uncharacterised variations between the different investigations and genetic heterogeneity  
261 within the Pashtun group are confounders. As many of the controls had non-malaria febrile illnesses  
262 it is possible, although unlikely, that the prevalence of G6PD deficiency is higher in such patients to  
263 that in the general population. In the initial clinical studies reported here severe anaemia was an  
264 exclusion criterion and this could have reduced the proportion of G6PD deficient patients. This study  
265 was confined to the G6PD Mediterranean genotype, so other G6PD polymorphisms were not  
266 studied, but these are unusual in the Pashtun so this is unlikely to have affected the results  
267 materially. Potential confounders become progressively more relevant as effects become smaller.

268 Overall this study shows that the G6PD Mediterranean genotype confers a very large and  
269 gene dose proportional protective effect against vivax malaria. This is not therefore a balanced  
270 polymorphism, and assuming the allele frequency is at equilibrium, it must be harmful. The main  
271 risks associated with G6PD deficiency are neonatal hyperbilirubinemia and haemolysis following  
272 oxidant food and drugs while the benefit is protection from malaria. Importantly for malaria  
273 treatment, the population risks associated with 8-aminoquinoline radical cure are greatly  
274 overestimated from G6PD prevalences in the healthy population.

## **Acknowledgements**

The investigators are grateful to the doctors, laboratory technicians, and malaria workers in the sites in Afghanistan, the Afghanistan National Malaria and Leishmania Control Program (NMLCP), the two provincial health directorates, and the senior management of the Ministry of Public Health and WHO-Afghanistan. We are also very grateful to the Molecular Tropical Medicine and Genetics laboratory staff in the Faculty of Tropical Medicine, Mahidol University for their help with genotyping.

## **Funding**

This work was supported by the Wellcome Trust. Dr Ghulam R. Awab was a Wellcome Trust tropical medicine training fellow. The studies were supported by the Wellcome Trust of Great Britain (Major Overseas Programme-Thailand Unit Core Grant: 106698/B/14/Z) and by the Wellcome Trust Principal Fellowship of NJ White.



## References

1. Beutler E. G6PD deficiency. *Blood*. 1994; 84: 3613–36.
2. Luzzatto L, Arese P. Favism and Glucose-6-Phosphate Dehydrogenase Deficiency. *N Engl J Med*. 2018; 378: 60-71.
3. Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, Hogg MM, Battle KE, Padilla CD, Baird JK, Hay SI. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. *PLoS Med*. 2012; 9(11): e1001339.
4. Mbanefo EC, Ahmed AM, Titouna A, Elmaraezy A, Trang NT, Phuoc Long N, Hoang Anh N, Diem Nghi T, The Hung B, Van Hieu M, Ky Anh N, Huy NT, Hirayama K. Association of glucose-6-phosphate dehydrogenase deficiency and malaria: a systematic review and meta-analysis. *Sci Rep*. 2017; 7: e45963.
5. Bienzle U, Ayeni O, Lucas AO, Luzzatto L. Glucose-6-phosphate dehydrogenase and malaria. Greater resistance of females heterozygous for enzyme deficiency and of males with non-deficient variant. *Lancet*. 1972; 1: 107–10.
6. Ruwende C, Khoo SC, Snow RW, Yates SN, Kwiatkowski D, Gupta S, Warn P, Allsopp CE, Gilbert SC, Peschu N, Newbold CI, Greenwood BM, Marsh K, Hill AV. Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria. *Nature*. 1995; 376: 246–9.
7. Guindo A, Fairhurst RM, Doumbo OK, Wellem TE, Diallo DA. X-linked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria. *PLoS Med*. 2007;4:e66.
8. Mombo LE, Ntoumi F, Bisseye C, Ossari S, Lu CY, Nagel RL, Krishnamoorthy R. Human genetic polymorphisms and asymptomatic *Plasmodium falciparum* malaria in Gabonese school children. *Am J Trop Med Hyg*. 2003; 68: 186–90.
9. Lopera-Mesa TM, Doumbia S, Konaté D, Anderson JM, Doumbouya M, Keita AS, Diakité SA, Traoré K, Krause MA, Diouf A, Moretz SE, Tullo GS, Miura K, Gu W, Fay MP, Taylor SM, Long CA,

- Diakité M, Fairhurst RM. Effect of red blood cell variants on childhood malaria in Mali: a prospective cohort study. *Lancet Haematol.* 2015; 2: e140-9.
10. Uyoga S, Ndila CM, Macharia AW, Nyutu G, Shah S, Peshu N, Clarke GM, Kwiatkowski DP, Rockett KA, Williams TN; MalariaGEN Consortium. Glucose-6-phosphate dehydrogenase deficiency and the risk of malaria and other diseases in children in Kenya: a case-control and a cohort study. *Lancet Haematol.* 2015; 2: e437-44.
11. Clarke GM, Rockett K, Kivinen K, Hubbard C, Jeffreys AE, Rowlands K, Jallow M, Conway DJ, Bojang KA, Pinder M, Usen S, Sisay-Joof F, Sirugo G, Toure O, Thera MA, Konate S, Sissoko S, Niangaly A, Poudiougou B, Mangano VD, Bougouma EC, Sirima SB, Modiano D, Amenga-Etego LN, Ghansah A, Koram KA, Wilson MD, Enimil A, Evans J, Amodu OK, Olaniyan S, Apinjoh T, Mugri R, Ndi A, Ndila CM, Uyoga S, Macharia A, Peshu N, Williams TN, Manjurano A, Sepúlveda N, Clark TG, Riley E, Drakeley C, Reyburn H, Nyirongo V, Kachala D, Molyneux M, Dunstan SJ, Phu NH, Quyen NN, Thai CQ, Hien TT, Manning L, Laman M, Siba P, Karunajeewa H, Allen S, Allen A, Davis TM, Michon P, Mueller I, Molloy SF, Campino S, Kerasidou A, Cornelius VJ, Hart L, Shah SS, Band G, Spencer CC, Agbenyega T, Achidi E, Doumbo OK, Farrar J, Marsh K, Taylor T, Kwiatkowski DP; MalariaGEN Consortium. Characterisation of the opposing effects of G6PD deficiency on cerebral malaria and severe malarial anaemia. *Elife.* 2017; 6: e15085.
12. Carter R, Mendis KN. Evolutionary and historical aspects of the burden of malaria. *Clin Microbiol Rev.* 2002; 15: 564-94.
13. Bouma MJ, Goris M, Akhtar T, Khan N, Khan N, Kita E. Prevalence and clinical presentation of glucose-6-phosphate dehydrogenase deficiency in Pakistani Pathan and Afghan refugee communities in Pakistan; implications for the use of primaquine in regional malaria control programmes. *Trans R Soc Trop Med Hyg.* 1995; 89: 62-64.
14. Leslie T, Bricen M, Mayan I, Mohammed N, Klinkenberg E, Hopkins Sibley C, Whitty CJM, Rowland M. The impact of phenotypic and genotypic G6PD deficiency on risk of *Plasmodium vivax*

- infection: A case-control study amongst Afghan refugees in Pakistan. *Plos Med*. 2010; 7; e1000283.
15. Jamornthanyawat N, Awab GR, Tanomsing N, Pukrittayakamee S, Yamin F, Dondorp AM, Day NP, White NJ, Woodrow CJ, Imwong M. A population survey of the glucose-6-phosphate dehydrogenase (G6PD) 563C>T (Mediterranean) mutation in Afghanistan. *PLoS One*. 2014; 9: e88605.
16. Awab GR, Imwong M, Bancone G, Jeeyapant A, Day NPJ, White NJ, Woodrow CJ. Chloroquine-Primaquine versus Chloroquine Alone to Treat Vivax Malaria in Afghanistan: An Open Randomized Superiority Trial. *Am J Trop Med Hyg*. 2017; 97:1782-1787.
17. Samilchuk E, D'Souza B, Al-Awadi S. Population study of common glucose-6-phosphate dehydrogenase mutations in Kuwait. *Hum Hered* 1999; 49: 41– 44.
18. Stan Development Team. 2018. The Stan Core Library, Version 2.18.0. <http://mc-stan.org>
19. Phyo AP, Jittamala P, Nosten FH, Pukrittayakamee S, Imwong M, White NJ, Duparc S, Macintyre F, Baker M, Möhrle JJ. Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with *Plasmodium falciparum* and *Plasmodium vivax* malaria: an open-label phase 2 trial. *Lancet Infect Dis*. 2016; 16: 61-69.
20. Pukrittayakamee S, Chantira A, Simpson JA, Vanijanonta S, Clemens R, Looareesuwan S, White NJ. Therapeutic responses to different antimalarial drugs in vivax malaria. *Antimicrob Agents Chemother*. 2000; 44: 1680-5.
21. Ebrahimipour M, Nateghpour M, Hajjarian H, Edrissian G, Jalali M, Raeisi A, Motevalli Haghi A, Farivar L, Khodadadi M, Rahimi-Froushani A. The Rate of *Plasmodium vivax* Infectivity within Glucose-6-Phosphate Dehydrogenase (G6PD) Deficient Individuals in Hormozgan Province, Iran. *Iran J Parasitol*. 2014; 9: 402-6.
22. Santana MS, Monteiro WM, Siqueira AM, Costa MF, Sampaio V, Lacerda MV, Alecrim MG. Glucose-6-phosphate dehydrogenase deficient variants are associated with reduced susceptibility to malaria in the Brazilian Amazon. *Trans R Soc Trop Med Hyg*. 2013; 107: 301-6.

23. Kurdi-Haidar B, Mason PJ, Berrebi A, Ankra-Badu G, al-Ali A, Oppenheim A, Luzzatto L. Origin and spread of the glucose-6-phosphate dehydrogenase variant (G6PD-Mediterranean) in the Middle East. *Am J Hum Genet.* 1990; 47: 1013-9.
24. Louicharoen C, Patin E, Paul R, Nuchprayoon I, Witoonpanich B, Peerapittayamongkol C, Casademont I, Sura T, Laird NM, Singhasivanon P, Quintana-Murci L, Sakuntabhai A. Positively selected G6PD-Mahidol mutation reduces *Plasmodium vivax* density in southeast Asians. *Science.* 2009; 326: 1546–9.
25. Yi H, Li H, Liang L, Wu Y, Zhang L, Qiu W, Jiang W, Yang F, Li Q, Yang Z, Wang C, Cui L, He Y. The glucose-6-phosphate dehydrogenase Mahidol variant protects against uncomplicated *Plasmodium vivax* infection and reduces disease severity in a Kachin population from northeast Myanmar. *Infect Genet Evol.* 2019; 75: e103980.
26. Khim N, Benedet C, Kim S, Kheng S, Siv S, Leang R, Lek S, Muth S, Chea N, Chuor CM, Duong S, Kerleguer A, Tor P, Chim P, Canier L, Witkowski B, Taylor WR, Ménard D. G6PD deficiency in *Plasmodium falciparum* and *Plasmodium vivax* malaria-infected Cambodian patients. *Malar J.* 2013;12: 171.
27. Dewasurendra RL, Rockett KA, Fernando SD, Carter R, Kwiatkowski DP, Karunaweera ND; MalariaGEN Consortium. G6PD gene variants and its association with malaria in a Sri Lankan population. *Malar J.* 2015; 14: 93.
28. Williams TN, Mwangi TW, Wambua S, Alexander ND, Kortok M, Snow RW, Marsh K. Sickle cell trait and the risk of *Plasmodium falciparum* malaria and other childhood diseases. *J Infect Dis.* 2005; 192: 178-86.
29. Watson JA, Leopold SJ, Simpson JA, Day NP, Dondorp AM, White NJ. Collider bias and the apparent protective effect of glucose-6-phosphate dehydrogenase deficiency on cerebral malaria. *Elife.* 2019; 8: e43154.
30. White NJ. Anaemia and malaria. *Malar J.* 2018 ;17: e371.

31. Leopold SJ, Watson JA, Jeeyapant A, Simpson JA, Phu NH, Hien TT, Day NPJ, Dondorp AM, White NJ. Investigating causal pathways in severe falciparum malaria:A pooled retrospective analysis of clinical studies. PLoS Med. 2019; 16: e1002858.

**Table**

Table 1 Summary of all case-control data included in the meta-analysis

		General population (controls)				<i>P. vivax</i> malaria (cases)			
		Awab	Leslie	Bouma		Awab	Leslie	Bouma	
		et al*	et al [14]	et al [13]	<b>Total</b>	et al*	et al [14]	et al [13]	<b>Total</b>
<b>males</b>	hemizygous	28	15	25	<b>68</b>	5	1	0	<b>6</b>
	normal	314	109	214	<b>637</b>	303	61	0	<b>364</b>
<b>females</b>	homozygous	2	2	0	<b>4</b>	3	0	0	<b>3</b>
	heterozygous	50	26	0	<b>76</b>	31	6	0	<b>37</b>
	normal	305	126	0	<b>431</b>	424	72	0	<b>496</b>

- Data from this report; 23 of 236 males from the earlier epidemiological study [15] and 5 of 106 male controls from the later studies were hemizygotes.

## Legends to Figures

Figure 1: Afghanistan: malaria stratification risk across all districts (Courtesy: National Malaria Strategic Plan 2013-2017). Blue circle shows area where the clinical malaria studies were performed.

Figure 1




Figure 1: Results from the meta-analysis assessing the protective effect of the Mediterranean variant of G6PD deficiency against *Plasmodium vivax* malaria. The posterior distributions over the percentage of G6PD<sup>Med</sup> individuals presenting with clinical vivax malaria relative to G6PD normal are shown for hemi/homozygotes (top) and heterozygotes (bottom). The circles show the mean estimates, with the 80% credible intervals shown by the thick blue lines and the 95% credible intervals shown by the thin blue lines.

Figure 2






Figure 1




Figure 2

